COPENHAGEN, May 8 (Reuters) - Danish pharmaceutical company H. Lundbeck said it had entered into a definitive agreement with Chelsea Therapeutics under which it will acquire the U.S. company.
Chelsea stockholders are entitled to $6.44 per share in cash and contingent value rights (CVRs) that may pay up to 1.50 dollar, corresponding to $658 million on a fully diluted basis, Lundbeck said.
The total potential consideration represents a premium of 59 percent over the closing price of Chelsea shares on May 7, Lundbeck added.
(Reporting by Teis Jensen; Editing by Pravin Char)
- Mergers, Acquisitions & Takeovers
- H. Lundbeck